Press Releases

 
Press Releases
  Date Title and Summary View
Apr 6, 2017
NOVATO, Calif. and LONDON, April 06, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for the treatment of X...
Mar 22, 2017
NOVATO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome (Glut1 DS) patients with s...
Mar 2, 2017
NOVATO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences: Shalini Sharp, the company's Chief Financia...
Feb 16, 2017
NOVATO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter and full year ended December 31, 2016. "In 2016 we a...
Feb 10, 2017
NOVATO, Calif., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will present at the LEERINK Partners 6th...
Feb 9, 2017
NOVATO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, February 16, 2017 at 5pm ET to discuss fourth quarter and full y...
Jan 5, 2017
NOVATO, Calif. and LONDON, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applicati...
Jan 4, 2017
NOVATO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 35th ...
Nov 30, 2016
Reductions observed in frequency and total duration of major medical events NOVATO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positi...
Nov 11, 2016
NOVATO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that is has withdrawn its conditional Marketing Authorization Application (MAA) from the European Medicines Age...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase